Evidence map›Paper›PMID 40397803›Full record

ArticleMolecular oncology2025

Loss of proton-sensing GPR4 reduces tumor progression in mouse models of colon cancer.

Leonie Perren, Moana Busch, Pedro A Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Leonie PerrenDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Moana BuschDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Pedro A RuizDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Ermanno MalagolaDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-9294-3097
Valeria BaumelerDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Federica FotiDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Adelina GrossDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Tobias GrütterDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Hendrik EdelDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Cordelia SchulerDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-2995-8170
Kristina HandlerInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-8952-6487
Glenn De LangeInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-6625-0606
Isabelle C ArnoldInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-8679-9666
Cheryl de VallièreDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Klaus SeuwenDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Martin HausmannDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-0696-0251
Gerhard RoglerDepartment of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_172870Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 314730_153380Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 320030-231749
6 · The paper itself

Abstract

We aimed to understand the role of G protein-coupled receptor 4 (GPR4) in tumorigenesis. GPR4 is a pH-sensing receptor that is activated by acidic extracellular pH. GPR4 is expressed primarily in vascular endothelial cells (ECs). Intestinal tissue from patients with inflammatory bowel disease (IBD) shows increased expression of GPR4. Patients with IBD have a significantly increased risk of developing colorectal cancer (CRC). In the MC38 model, Gpr4-deficient mice showed significantly reduced tumor size and weight compared to wild-type (WT) mice. This effect correlated with a significant increase in IL2 protein and natural killer (NK)1.1

Indexed as

colorectal cancerGPR4inflammatory bowel diseasepH‐sensing G protein‐coupled receptors

Identifiers

PMID40397803
PMCPMC12330923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.